Accent Microcell LtdNSE:ACCENTMIC
Current view Q4 2026
Risky. Its one growth plant has been delayed twice and still earns nothing; this year's sales growth came from thin-margin reselling, not real products. Wait for the plant to actually run.
Latest exchange filings last 5 · 5 after Q4 2026
- 13 Aug ’26Purchase order placed with Inox Wind for 4.45 MW wind turbine installation on 12 August 2026. ↗
- 1 Aug ’26Accent Microcell’s 14th AGM voting results: all nine resolutions passed on 31 July 2026. ↗
- 31 Jul ’26AGM approved FY26 audited accounts, ₹1 dividend, director reappointments, and new independent director. ↗
- 31 Jul ’2614th AGM held on 31 July 2026; all resolutions passed, including ₹1 final dividend and director reappointments. ↗
- 9 Jul ’26Published AGM notice, book closure, and remote e-voting details for 14th AGM on 9 July 2026. ↗
Exchange filings, with the company's own one-line summary, read off the same page as the figures. Screener publishes only the most recent few, so this is the last 5 — not everything filed since your note, and a quiet-looking list is not proof of a quiet quarter. A filing is marked new when it is dated after the end of the quarter your note covers. Not scored, and not a judgement — a routine repayment notice and a takeover sit in the same list.
AI concall report · Q4 2026
The full earnings-call read behind this view — what management promised, what they delivered, and the earning trigger.
Growth Q4 2026
| Metric | This year vs lastYoY · vs Q4 2025 | vs the quarter beforeQoQ, sequential · vs Q3 2026 | 3-year yearly average3Y CAGR · compounded | 5-year yearly average5Y CAGR · compounded |
|---|---|---|---|---|
| Sales | ▲ +51.1% | +51.1% | +21.0% | +21.3% |
| Operating profit | ▲ +43.5% | +37.5% | +45.0% | +37.5% |
| EPS | ▲ +55.4% | +42.8% | +30.3% | +13.3% |
| PAT | ▲ +52.9% | +44.4% | — | — |
Tinted rows drive the Tier. Tier = the weaker of YoY Sales and YoY PAT growth. Here the weaker is Sales at +51.1%, which is ≥ 20% → Tier 1.
QoQ is sequential, not a trend. For most Indian companies the March quarter is seasonally the largest, so a June-quarter fall against it is a calendar effect. Only the YoY column feeds the Tier.
Multibagger potential
Average58/100
Growing fast — and the market has noticed. Profit per share grew 30% a year, and buyers now pay more for each rupee of it than they did a year ago. Some of the re-pricing has already happened.
₹675 → ₹1,350 needs the P/E at 33× — it is 37× today, and has ranged 13× to 38× over the last 5 years. The rest would come from earnings growing as they have.
What you pay for its profitlog scale · 5-year range
Tripling needs 50× — never traded above 38× in 5 years.
At ₹377 the price-tag on its earnings reaches the 21× it is being projected toward — the point where being cheap against that yardstick is used up.
Re-rated already, on growth that doesn't fully back it.
How this is calculated
This is arithmetic, not a forecast — Return = ΔEPS × ΔMultiple. It says what would have to be true, not how likely it is, and "earnings keep growing at this rate for three more years" is the assumption doing the most work. This is a small-cap at ₹1,584 cr, so the odds of a re-rate are not fighting its own size.
Growth rate used: 30.3% — the weakest of EPS / Sales / Op-profit from 3-year EPS CAGR. Latest quarter reads 55%.
How it compares with its rivals Healthcare · 6 of 159 listed
These are the industry's largest names rather than companies of its own size, so the columns are worth reading straight across — a ranking against them would only be restating the size gap.
| Company | Price | P/E | Size | ROCE | Profitlast qtr | Saleslast qtr |
|---|---|---|---|---|---|---|
| Accent Microcell | ₹678 | 37.0× | ₹1,625 Cr | 24.9% | +55.4% | +51.3% |
| Sun Pharma.Inds. | ₹1,851 | 35.1× | ₹4.44 L Cr | 20.5% | +6.0% | +10.5% |
| Divi's Lab. | ₹9,379 | 83.5× | ₹2.49 L Cr | 22.0% | +65.5% | +27.8% |
| Torrent Pharma. | ₹4,858 | 82.8× | ₹1.85 L Cr | 15.2% | +5.8% | +54.9% |
| Zydus Lifesci. | ₹1,153 | 23.6× | ₹1.15 L Cr | 21.1% | −35.1% | +22.0% |
| Cipla | ₹1,374 | 31.0× | ₹1.11 L Cr | 15.5% | −39.2% | +2.3% |
Screener's own peer group, from the request already made for the industry P/E. It serves the industry's largest names by market cap, not companies of a similar size, so treat this as context rather than a like-for-like table; this company is always shown. On a phone the price, size and sales columns are dropped rather than pushed off the edge. Not part of the score.
Business quality to Jun 2026
| Are the margins widening? | slightly narrower than 2.5 years earlier | operating margin 18% → 16% over 2.5 years |
|---|---|---|
| Did the profit turn into cash? | most of it, with some tied up | 56% last year, 62% over three · free cash flow −₹68 cr, positive in 2 of 5 years |
| Is the growth borrowed? | essentially debt-free | ₹1 cr — 0.00× its own equity (was 0.01×) |
| Is it being collected? | collection is steady | 95 days to collect, up 6 in a year · cash cycle 117 days |
| Who has been buying? | the promoters have been selling | promoters 53.0% (−2.1 in a year), 55.1% → 53.0% over 2.3 years · FIIs 0.9% (+0.9) · DIIs 3.5% (+0.7) · shareholders 2,418 → 3,178 |
| What does it earn on its capital? | earns a high return on the capital it employs | ROCE 24.9% · ROE 18.6% |
Fetched from the filings, not typed — and deliberately not part of the score. These are the questions the score cannot ask: it reads growth, price and trend, so a company can score well while its profit never becomes cash. Weigh these beside the note, not against the number.
Screener's own checklist not mine, not the score
In its favour
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 54.3% CAGR over last 5 years
Against it
- Promoter holding has decreased over last quarter: -2.45%
Generated by screener.in from a fixed checklist — not written by me and not an input to the score. It is here as a second machine opinion to weigh against the note; where it disagrees with the view above, the note is the considered one.